Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

A gathering of global perspectives ….. a look at DIA’s annual meeting: Post 1 of 2

Posted on July 11th, 2016 by

Pharma R&D

DIA’s annual meeting

At the end of June, the Drug Information Association (DIA), held its annual conference with this year’s theme being “A Gathering of Global Perspectives.”  The meeting, held in Philadelphia, offered a wide variety of tracks from which you could “pick and mix” Continue reading “A gathering of global perspectives ….. a look at DIA’s annual meeting: Post 1 of 2” »

Text Mining for Pharmacovigilance Purposes

Posted on July 7th, 2016 by



Text mining, or text data mining, is the process of retrieving relevant information from large amounts of ‘unstructured’ text with the help of automated pattern learning. Continue reading “Text Mining for Pharmacovigilance Purposes” »

Reducing the Risk of Late-Phase Failures

Posted on July 5th, 2016 by

Pharma R&D


Late-stage failures are common. The likelihood of a phase transition from Phase 2 to 3 is about 30%, and moving from Phase 3 to submission is only about 60% likely. The majority of late-stage failures are due to a lack of demonstrated efficacy (56%), followed by safety issues (28%)[1]. Continue reading “Reducing the Risk of Late-Phase Failures” »

How Better Data is Reducing Drug Development Costs

Posted on July 1st, 2016 by

Pharma R&D


We’ve all heard how expensive it is to bring a drug to market. Depending on who you ask, the costs have risen somewhere between USD 1.6 and 2.6 billion.  Continue reading “How Better Data is Reducing Drug Development Costs” »

How will Brexit effect Multinationals and Pharmaceutical Companies?

Posted on June 30th, 2016 by

Pharma R&D


One of the most stunning upsets to happen in global politics in decades transpired on June 23 when the people of the United Kingdom voted to leave the European Union. Continue reading “How will Brexit effect Multinationals and Pharmaceutical Companies?” »

The Fundamentals of Good Data Stewardship

Posted on June 29th, 2016 by

Pharma R&D


Bioactivity data is not in short supply. The days of limited availability of data on compounds and biological targets are long behind us. Continue reading “The Fundamentals of Good Data Stewardship” »

  1. 1
  2. 44
  3. 45
  4. 46
  5. 47
  6. 48
  7. 60

About this Blog


The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.